Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.

ABSTRACT: The majority of patients with chronic myeloid leukemia are successfully managed with life-long treatment with tyrosine kinase inhibitors. In patients in chronic phase, other malignancies are among the most common causes of death, raising concerns on the relationship between these deaths and the off-target effects of tyrosine kinase inhibitors. We analyzed the incidence of second primary malignancies, and related mortality, in 514 chronic myeloid leukemia patients enrolled in clinical trials in which imatinib was given as first-line treatment. We then compared the observed incidence and mortality with those expected in the age- and sex-matched Italian general population, calculating standardized incidence and standardized mortality ratios. After a median follow-up of 74 months, 5.8% patient

SUBMITTER: Gugliotta G 

PROVIDER: S-EPMC5685244 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature